We decided to focus on BCL2, because it is the sole target for which an FDA/EMA-approved drug is available for the treatment of specific blood cancers (in particular, acute myeloid leukemia, chronic lymphocytic leukemia and small lymphocytic leukemia) (23). This evidence concerns the gene BCL2 and hematopoietic and lymphoid system neoplasm.